Liposomal formulations of poorly soluble camptothecin: Drug retention and biodistribution

Journal of Liposome Research

Volumn 23, Issue 1, 2013, Pages 70-81

  Flaten, Goril Eide ^a,b   Chang, Ting Tung ^b,d   Phillips, William T ^b   Brandl, Martin ^a,c   Bao, Ande ^b   Goins, Beth ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

111In labeled liposomes; 3H labeled CPT; Colon cancer; HT 29 mouse tumor xenograft model; Scintigraphic imaging

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CAMPTOTHECIN; INDIUM 111; LIPOSOME; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG LABELING; DRUG LIVER LEVEL; DRUG RELEASE; DRUG RETENTION; DRUG SOLUBILITY; GAMMA SCINTIGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPID COMPOSITION; LIQUID SCINTILLATION COUNTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SAMPLING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT; ULTRACENTRIFUGATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LIPOSOMES; MICE; NEOPLASMS; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 84873301372     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2012.742537     Document Type: Article

References (83)

1. Atyabi, F., Farkhondehfai, A., Esmaeili, F., Dinarvand, R. (2009). Preparation of pegylated nano-liposomal formulation containing SN-38: in vitro characterization and in vivo biodistribution in mice. Acta Pharm 59:133-144.
2. Awasthi, V., Goins, B., Klipper, R., Loredo, R., Korvick, D., Phillips, W. T. (1998). Imaging experimental osteomyelitis using radiolabeled liposomes. J Nucl Med 39:1089-1094. (Pubitemid 28270133)
3. Awasthi, V. D., Goins, B., Klipper, R., Phillips, W. T. (2002). Accumulation of PEG-liposomes in the inflamed colon of rats: potential for therapeutic and diagnostic targeting of inflammatory bowel diseases. J Drug Target 10:419-427.
4. Bao, A., Goins, B., Klipper, R., Negrete, G., Phillips, W. T. (2004). Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther 308:419-425. (Pubitemid 38134199)
5. Berrada, M., Serreqi, A., Dabbarh, F., Owusu, A., Gupta, A., Lehnert, S. (2005). A novel non-toxic camptothecin formulation for cancer chemotherapy. Biomaterials 26:2115-2120. (Pubitemid 39575354)
6. Bom, D., Curran, D. P., Kruszewski, S., Zimmer, S. G., Thompson Strode, J., Kohlhagen, G., et al. (2000). The novel silatecan 7-tert-butyldimethylsilyl- 10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43:3970-3980.
7. Bom, D., Curran, D. P., Zhang, J., Zimmer, S. G., Bevins, R., Kruszewski, S., et al. (2001). The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release 74:325-333. (Pubitemid 32727640)
8. Bordi, F., Cametti, C., Sennato, S., Diociaiuti, M. (2006). Direct evidence of multicompartment aggregates in polyelectrolyte-charged liposome complexes. Biophys J 91:1513-1520. (Pubitemid 44174268)
9. Brandl, M. (2001). Liposomes as drug carriers: a technological approach. Biotechnol Annu Rev 7:59-85. (Pubitemid 41081525)
10. Brandl, M. (2003). Liposomal drug carriers for cancer diagnosis and therapy. In: Budman, D. R., Calvert, A. H., Rowinsky, E. K. (Eds.), Handbook of anticancer drug development (pp. 225-236). Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins.
11. Burke, T. G. (1996). Liposomal and micellar stabilization of camptothecin drugs. U.S. patent application 5,552,156.
12. Burke, T. G., Bom, D. (2000). Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo. Ann N Y Acad Sci 922:36-45. (Pubitemid 32050855)
13. Burke, T. G., Gao, X. (1994). Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J Pharm Sci 83:967-969. (Pubitemid 24228546)
14. Burke, T. G., Mishra, A. K., Wani, M. C., Wall, M. E. (1993). Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32:5352-5364. (Pubitemid 23167976)
15. Burke, T. G., Staubus, A. E., Mishra, A. K., Malak, H. (1992). Liposomal stabilization of camptothecins lactone ring. J Am Chem Soc 114:8318-8319.
16. Chen, J., Cai, B., Ping, Q., Liu, M., Guo, J. (2008). Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection. Drug Dev Ind Pharm 34:853-859.
17. Chen, J., Ping, Q. N., Guo, J. X., Chu, X. Z., Song, M. M. (2006). Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin. Drug Dev Ind Pharm 32:719-726. (Pubitemid 44181199)
18. Chonn, A., Semple, S. C., Cullis, P. R. (1991). Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma-proteins which mediate liposome clearance in vivo. Biochim Biophys Acta 1070:215-222.
19. Chou, T. H., Chen, S. C., Chu, I. M. (2003). Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method. J Biosci Bioeng 95:405-408.
20. Clements, M. K., Wasi, S., Daoud, S. S. (1996). Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro. Anticancer Drugs 7:851-857. (Pubitemid 26421238)
21. Colbern, G. T., Dykes, D. J., Engbers, C., Musterer, R., Hiller, A., Pegg, E., et al. (1998). Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin Cancer Res 4:3077-3082. (Pubitemid 29001484)
22. Dadashzadeh, S., Vali, A. M., Rezaie, M. (2008). The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int J Pharm 353:251-259.
23. Daoud, S. S., Fetouh, M. I., Giovanella, B. C. (1995). Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts. Anticancer Drugs 6:83-93.
24. Desjardins, J. P., Abbott, E. A., Emerson, D. L., Tomkinson, B. E., Leray, J. D., Brown, E. N., et al. (2001). Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anticancer Drugs 12:235-245. (Pubitemid 32269920)
25. Drummond, D. C., Noble, C. O., Guo, Z., Hayes, M. E., Connolly-Ingram, C., Gabriel, B. S., et al. (2010). Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Rel 141:13-21.
26. Drummond, D. C., Noble, C. O., Guo, Z., Hong, K., Park, J. W., Kirpotin, D. B. (2006). Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 66:3271-3277.
27. Eichhorn, M. E., Luedemann, S., Strieth, S., Papyan, A., Ruhstorfer, H., Haas, H., et al. (2007). Cationic lipid complexed camptothecin (EndoTAG-2) improves antitumoral efficacy by tumor vascular targeting. Cancer Biol Ther 6:920-929. (Pubitemid 351574983)
28. ElBayoumi, T. A., Torchilin, V. P. (2009). Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, longcirculating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 15:1973-1980.
29. Emerson, D. L. (2000). Liposomal delivery of camptothecins. Pharm Sci Technolo Today 3:205-209. (Pubitemid 30364934)
30. Emerson, D. L., Bendele, R., Brown, E., Chiang, S., Desjardins, J. P., Dihel, L. C., et al. (2000). Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin Cancer Res 6:2903-2912. (Pubitemid 30482133)
31. Fahr, A., Van Hoogevest, P., Kuntsche, J., Leigh, M. L. S. (2006). Lipophilic drug transfer between liposomal and biological membranes: What does it mean for parenteral and oral drug delivery? J Liposome Res 16:281-301. (Pubitemid 44359001)
32. Forssen, E. A., Ross, M. E. (1994). Daunoxome® treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 4:481-512. (Pubitemid 24130557)
33. Garcia-Carbonero, R., Supko, J. G. (2002). Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641-661. (Pubitemid 34742090)
34. Gilbert, B. E., Seryshev, A., Knight, V., Brayton, C. (2002). 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs. Inhal Toxicol 14:185-197. (Pubitemid 34184958)
35. Goins, B., Klipper, R., Rudolph, A. S., Phillips, W. T. (1994). Use of technetium-99m-liposomes in tumor imaging. J Nucl Med 35:1491-1498. (Pubitemid 24280459)
36. Goins, B., Phillips, W. T. (2003). Radiolabelled liposomes for imaging and biodistribution studies. In: Torchilin, V. P., Wessig, V. (Eds.), Liposomes, 2nd ed. (pp. 319-336). New York: Oxford University Press.
37. Grohganz, H., Ziroli, V., Massing, U., Brandl, M. (2003). Quantification of various phosphatidylcholines in liposomes by enzymatic assay. AAPS Pharm Sci Tech 4:E63.
38. Gurung, P., Young, B. M., Coleman, R. A., Wiechert, S., Turner, L. E., Ray, N. B., et al. (2009). Chronic ethanol induces inhibition of antigen-specific CD8+ but not CD4+ immunodominant T cell responses following Listeria monocytogenes inoculation. J Leuk Biol 85:34-43.
39. Hatefi, A., Amsden, B. (2002). Camptothecin delivery methods. Pharm Res 19:1389-1399. (Pubitemid 35266542)
40. Hattori, Y., Shi, L., Ding, W., Koga, K., Kawano, K., Hakoshima, M., et al. (2009). Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Control Releas 136:30-37.
41. Kawano, K., Watanabe, M., Yamamoto, T., Yokoyama, M., Opanasopit, P., Okano, T., et al. (2006). Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J Control Release 112:329-332.
42. Kelly, C., Jefferies, C., Cryan, S. A. (2011). Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011:727241.
43. Koshkina, N. V., Gilbert, B. E., Waldrep, J. C., Seryshev, A., Knight, V. (1999). Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol 44:187-192. (Pubitemid 29350173)
44. Kruszewski, S., Burke, T. G. (2002). Camptothecins affinity to HSA and membranes determined by fluorescence anisotropy measurements. Optica Applicata 32:721-730.
45. Lei, S., Chien, P. Y., Sheikh, S., Zhang, A., Ali, S., Ahmad, I. (2004). Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice. Anticancer Drugs 15: 773-778. (Pubitemid 39281301)
46. Li, X., Hirsh, D. J., Cabral-Lilly, D., Zirkel, A., Gruner, S. M., Janoff, A. S., et al. (1998). Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1415:23-40. (Pubitemid 29050759)
47. Liu, J. J., Hong, R. L., Cheng, W. F., Hong, K., Chang, F. H., Tseng, Y. L. (2002). Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation. Anticancer Drugs 13:709-717.
48. Loos, W. J., Kehrer, D., Brouwer, E., Verweij, J., De Bruijn, P., Hamilton, M., et al. (2000). Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversedphase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 738:155-163. (Pubitemid 30053103)
49. MacKenzie, M. J., Hirte, H. W., Siu, L. L., Gelmon, K., Ptaszynski, M., Fisher, B., et al. (2004). A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol 15:665-670. (Pubitemid 38559606)
50. Maitani, Y., Katayama, S., Kawano, K., Hayama, A., Toma, K. (2008). Artificial lipids stabilized camptothecin incorporated in liposomes. Biol Pharm Bull 31:990-993. (Pubitemid 351732013)
51. Matsumura, Y., Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392. (Pubitemid 17221789)
52. Mi, Z., Burke, T. G. (1994). Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33:10325-10336. (Pubitemid 24281798)
53. Min, K. H., Park, K., Kim, Y. S., Bae, S. M., Lee, S., Jo, H. G., et al. (2008). Hydrophobically modified glycol chitosan nanoparticlesencapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release 127:208-218.
54. Mougin-Degraef, M., Bourdeau, C., Jestin, E., Sai-Maurel, C., Bourgeois, A., Remaud-Le Saec, P., et al. (2007). Doubly radiolabeled liposomes for pretargeted radioimmunotherapy. Int J Pharm 344:110-117. (Pubitemid 47495979)
55. Ogihara, I., Kojima, S., Jay, M. (1986). Differential uptake of gallium-67- labeled liposomes between tumors and inflammatory lesions in rats. J Nucl Med 27:1300-1307. (Pubitemid 17030126)
56. Ogiso, T., Niinaka, N., Iwaki, M. (1996). Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. J Pharm Sci 85:57-64. (Pubitemid 26029626)
57. Perez-Soler, R., Sugarman, S. M., Poirot, K. R. (1998). Lipid complexed topoisomerase I inhibitors. U.S. patent application 5,834,012.
58. Phillips, W. T., Goins, B. (2002). Assessment of liposome delivery using scintigraphic imaging. J Liposome Res 12:71-80. (Pubitemid 34846959)
59. Phillips, W. T., Goins, B. A., Bao, A. (2009). Radioactive liposomes. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:69-83.
60. Proulx, M. E., Desormeaux, A., Marquis, J. F., Olivier, M., Bergeron, M. G. (2001). Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother 45:2623-2627. (Pubitemid 32801920)
61. Sadzuka, Y. (2000). Effective prodrug liposome and conversion to active metabolite. Curr Drug Metab 1:31-48.
62. Sadzuka, Y., Hirota, S. (1997). Effect of CPT-11 on lipid peroxide level in mouse tissues. Jpn J Cancer Res 88:512-516. (Pubitemid 27267615)
63. Sadzuka, Y., Hirotsu, S., Hirota, S. (1998). Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT- 11. Cancer Lett 127:99-106. (Pubitemid 28230791)
64. Sadzuka, Y., Hirotsu, S., Hirota, S. (1999). Effective irinotecan (CPT- 11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Jpn J Cancer Res 90:226-232. (Pubitemid 29112324)
65. Sadzuka, Y., Takabe, H., Sonobe, T. (2005). Liposomalization of SN-38 as active metabolite of CPT-11. J Control Release 108:453-459. (Pubitemid 41608676)
66. Saetern, A. M., Brandl, M., Bakkelund, W. H., Sveinbjornsson, B. (2004a). Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro. Anticancer Drugs 15:899-906. (Pubitemid 39482931)
67. Saetern, A. M., Flaten, G. E., Brandl, M. (2004b). A method to determine the incorporation capacity of camptothecin in liposomes. AAPS Pharm Sci Tech 5:e40.
68. Senmaru, N., Shichinohe, T., Takeuchi, M., Miyamoto, M., Sazawa, A., Ogiso, Y., et al. (1998). Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y. Int J Cancer 78:366-371. (Pubitemid 28445376)
69. Sou, K., Goins, B., Leland, M. M., Tsuchida, E., Phillips, W. T. (2010). Bone marrow-targeted liposomal carriers: a feasibility study in nonhuman primates. Nanomedicine (Lond) 5:41-49.
70. Stella, V. J., Rajewski, R. A. (1997). Cyclodextrins: their future in drug formulation and delivery. Pharm Res 14:556-567. (Pubitemid 27220271)
71. Subramanian, D., Muller, M. T. (1995). Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. Oncol Res 7:461-469. (Pubitemid 26005411)
72. Sugarman, S. M., Zou, Y. Y., Wasan, K., Poirot, K., Kumi, R., Reddy, S., et al. (1996). Lipid complexed camptothecin: Formulation and initial biodistribution and antitumor activity studies. Cancer Chemother Pharmacol 37:531-538. (Pubitemid 26080150)
73. Tardi, P., Choice, E., Masin, D., Redelmeier, T., Bally, M., Madden, T. D. (2000). Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60:3389-3393. (Pubitemid 30482152)
74. Tomayko, M. M., Reynolds, C. P. (1989). Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148-154. (Pubitemid 19163397)
75. Torchilin, V. P., Weissig, V. (2003). Liposomes. Oxford, UK: Oxford University Press.
76. Watanabe, M., Kawano, K., Toma, K., Hattori, Y., Maitani, Y. (2008). In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. J. Control Release 127:231-238.
77. Watanabe, M., Kawano, K., Yokoyama, M., Opanasopit, P., Okano, T., Maitani, Y. (2006). Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int J Pharm 308:183-189. (Pubitemid 43097251)
78. Wilson, K. D., Raney, S. G., Sekirov, L., Chikh, G., Dejong, S. D., Cullis, P. R., Tam, Y. K. (2007). Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake, and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int Immunopharmacol 7:1064-1075. (Pubitemid 46891326)
79. Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., Yang, C. Z. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 59:299-307. (Pubitemid 29238174)
80. Yang, Y., Ma, Y., Wang, S. (2012). A novel method to load topotecan into liposomes driven by a transmembrane NH(4)EDTA gradient. Eur J Pharm Biopharm 80:332-339.
81. Zhang, J. A., Xuan, T., Parmar, M., Ma, L., Ugwu, S., Ali, S., et al. (2004). Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 270:93-107. (Pubitemid 38077091)
82. Zhang, Z., Yao, J. (2012). Preparation of irinotecan-loaded folatetargeted liposome for tumor targeting delivery and its antitumor activity. AAPS PharmSciTech 13:802-810.
83. Zucker, D., Andriyanov, A. V., Steiner, A., Raviv, U., Barenholz, Y. (2012). Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. J Control Release 160:281-289.